Related Experiment Video
Updated: Jun 6, 2026
07:59
Bedside Ultrasound for Guiding Fluid Removal in Patients with Pulmonary Edema: The Reverse-FALLS Protocol
Published on: July 28, 2018
Managing hyponatremia in patients with heart failure
1Department of Internal Medicine, University of California, San Diego, San Diego, California. bgreenberg@ucsd.edu.
Journal of Hospital Medicine
|December 16, 2010
Summary
Hyponatremia, or low serum sodium, affects 20% of heart failure patients. Arginine vasopressin (AVP) blockers can safely increase sodium levels by promoting free water excretion, improving outcomes.
Area of Science:
- Cardiology
- Nephrology
- Endocrinology
Background:
- Hyponatremia affects approximately 20% of hospitalized heart failure patients, worsening outcomes.
- Nonosmotic release of arginine vasopressin (AVP) is a key factor in developing hyponatremia in heart failure.
- Current treatments for hyponatremia in heart failure have limited efficacy.
Purpose of the Study:
- To review the theoretical basis and clinical evidence for using AVP receptor antagonists in heart failure patients with hyponatremia.
- To evaluate the efficacy and safety of AVP blockers in managing low serum sodium levels in heart failure.
Main Methods:
- Review of the physiological role of AVP in water balance and sodium regulation.
- Analysis of clinical trial data on the administration of AVP receptor antagonists to euvolemic and hypervolemic patients.
- Assessment of effects on serum sodium, free water excretion, and adverse events.
Main Results:
- AVP blockers increase free water excretion, leading to weight loss and elevated serum sodium levels.
- Clinical trials demonstrate the safety of AVP blockers during long-term administration in heart failure patients.
- No significant major adverse effects were reported with AVP blocker treatment.
Conclusions:
- AVP receptor antagonists are a promising therapeutic option for heart failure patients with hyponatremia.
- These agents effectively increase serum sodium levels and are well-tolerated.
- Consideration of AVP antagonists is warranted for heart failure patients with significant hyponatremia.
Related Concept Videos
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:22Heart Failure Drugs: Diuretics
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
01:22Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
01:30Heart Failure VII: Nursing Interventions
The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
01:28Mitral Regurgitation IV: Nursing Management
Mitral regurgitation (MR) is a condition where the mitral valve does not close properly, leading to the backward flow of blood from the left ventricle into the left atrium during systole. This condition can arise from various causes, including rheumatic fever, infective endocarditis, or degenerative valve disease. Effective nursing management is crucial to optimizing patient outcomes and involves comprehensive assessment and targeted interventions.Comprehensive Patient AssessmentA detailed...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...